Suppr超能文献

相似文献

4
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.
Clin Cancer Res. 2006 Mar 15;12(6):1707-14. doi: 10.1158/1078-0432.CCR-05-2338.
9
[Impact of biological function on ovarian clear cell carcinoma ES2 cell line with ARID1A gene expression down-regulating in vitro].
Zhonghua Fu Chan Ke Za Zhi. 2016 Mar;51(3):209-15. doi: 10.3760/cma.j.issn.0529-567X.2016.03.009.

引用本文的文献

3
Utility of Matrix Metalloproteinases in the Diagnosis, Monitoring and Prognosis of Ovarian Cancer Patients.
Cancer Manag Res. 2022 Nov 30;14:3359-3382. doi: 10.2147/CMAR.S385658. eCollection 2022.
4
Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition.
Bioconjug Chem. 2022 May 18;33(5):795-806. doi: 10.1021/acs.bioconjchem.2c00059. Epub 2022 Apr 21.
5
The role of MMP-14 in ovarian cancer: a systematic review.
J Ovarian Res. 2021 Aug 3;14(1):101. doi: 10.1186/s13048-021-00852-7.
6
The Trinity of Matrix Metalloproteinases, Inflammation, and Cancer: A Literature Review of Recent Updates.
Antiinflamm Antiallergy Agents Med Chem. 2020;19(3):206-221. doi: 10.2174/1871523018666191023141807.
7
Screening, epidemiology, molecular biology, and treatment strategies for endometriosis-associated ovarian cancer.
Reprod Med Biol. 2009 Sep 26;9(1):17-22. doi: 10.1007/s12522-009-0034-9. eCollection 2010 Mar.
10
Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer.
Diagn Pathol. 2016 Apr 2;11:34. doi: 10.1186/s13000-016-0485-3.

本文引用的文献

1
Cancer statistics, 2008.
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
3
Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis.
Semin Cell Dev Biol. 2008 Feb;19(1):24-33. doi: 10.1016/j.semcdb.2007.06.008. Epub 2007 Jul 10.
4
MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells.
Br J Cancer. 2007 Aug 6;97(3):358-67. doi: 10.1038/sj.bjc.6603863. Epub 2007 Jul 3.
5
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Gynecol Oncol. 2007 May;105(2):404-8. doi: 10.1016/j.ygyno.2006.12.024. Epub 2007 Feb 9.
8
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.
Clin Cancer Res. 2006 Mar 15;12(6):1707-14. doi: 10.1158/1078-0432.CCR-05-2338.
9
Matrix metalloproteases in head and neck cancer.
Head Neck. 2006 Jul;28(7):639-48. doi: 10.1002/hed.20365.
10
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Clin Cancer Res. 2005 Sep 15;11(18):6422-30. doi: 10.1158/1078-0432.CCR-05-0508.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验